Preoperative CA125 Significantly Improves Risk Stratification in High-Grade Endometrial Cancer
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
PubMed
37174070
PubMed Central
PMC10177432
DOI
10.3390/cancers15092605
PII: cancers15092605
Knihovny.cz E-zdroje
- Klíčová slova
- CA125, advanced stage, endometrial cancer, high-grade, outcome,
- Publikační typ
- časopisecké články MeSH
Patients with high-grade endometrial carcinoma (EC) have an increased risk of tumor spread and lymph node metastasis (LNM). Preoperative imaging and CA125 can be used in work-up. As data on cancer antigen 125 (CA125) in high-grade EC are limited, we aimed to study primarily the predictive value of CA125, and secondarily the contributive value of computed tomography (CT) for advanced stage and LNM. Patients with high-grade EC (n = 333) and available preoperative CA125 were included retrospectively. The association of CA125 and CT findings with LNM was analyzed by logistic regression. Elevated CA125 ((>35 U/mL), (35.2% (68/193)) was significantly associated with stage III-IV disease (60.3% (41/68)) compared with normal CA125 (20.8% (26/125), [p < 0.001]), and with reduced disease-specific-(DSS) (p < 0.001) and overall survival (OS) (p < 0.001). The overall accuracy of predicting LNM by CT resulted in an area under the curve (AUC) of 0.623 (p < 0.001) independent of CA125. Stratification by CA125 resulted in an AUC of 0.484 (normal), and 0.660 (elevated). In multivariate analysis elevated CA125, non-endometrioid histology, pathological deep myometrial invasion ≥50%, and cervical involvement were significant predictors of LNM, whereas suspected LNM on CT was not. This shows that elevated CA125 is a relevant independent predictor of advanced stage and outcome specifically in high-grade EC.
Centre for Cancer Biomarkers Department of Clinical Science University of Bergen 5020 Bergen Norway
Department of Gynecology Catharina Hospital 5623 EJ Eindhoven The Netherlands
Department of Obstetrics and Gynaecology Rijnstate Hospital 6815 AD Arnhem The Netherlands
Department of Obstetrics and Gynecology Amphia Hospital Breda 4818 CK Breda The Netherlands
Department of Obstetrics and Gynecology Bichat Claude Bernard Hospital 75018 Paris France
Department of Obstetrics and Gynecology Elkerliek Hospital 5751 CB Helmond The Netherlands
Department of Obstetrics and Gynecology Haukeland University Hospital 5021 Bergen Norway
Department of Obstetrics and Gynecology Hospital del Mar Parc de Salut Mar 08003 Barcelona Spain
Department of Obstetrics and Gynecology Maxima Medical Centre 5631 BM Veldhoven The Netherlands
Department of Oncology KU Leuven 3000 Leuven Belgium
Department of Pathology Canisius Wilhelmina Hospital 6532 SZ Nijmegen The Netherlands
Department of Pathology Eurofins PAMM 5623 EJ Eindhoven The Netherlands
Department of Pathology Radboud University Medical Center 6525 GA Nijmegen The Netherlands
Department of Pathology University of Turku 20500 Turku Finland
Department of Radiation Oncology Radboud University Medical Center 6525 GA Nijmegen The Netherlands
Institute of Pathology University Medical Center 79104 Freiburg Germany
Radboud Institute of Health Sciences 6525 GA Nijmegen The Netherlands
Zobrazit více v PubMed
Stålberg K., Kjølhede P., Bjurberg M., Borgfeldt C., Dahm-Kähler P., Falconer H. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group. Int. J. Cancer. 2017;140:2693–2700. doi: 10.1002/ijc.30707. PubMed DOI
Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:16–41. doi: 10.1093/annonc/mdv484. PubMed DOI PMC
Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A.B. Endometrial cancer: A review and current management strategies: Part I. Gynecol. Oncol. 2014;134:85–92. doi: 10.1016/j.ygyno.2014.05.018. PubMed DOI
Holloway R.W., Abu-Rustum N.R., Backes F.J., Boggess J.F., Gotlieb W.H., Lowery W.J., Rossi E.C., Tanner E.J., Wolsky R.J. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol. Oncol. 2017;146:405–415. doi: 10.1016/j.ygyno.2017.05.027. PubMed DOI PMC
Creasman W.T., Ali S., Mutch D.G., Zaino R.J., Powell M.A., Mannel R.S., Backes F.J., DiSilvestro P.A., Argenta P.A., Pearl M.L., et al. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol. Oncol. 2017;145:519–525. doi: 10.1016/j.ygyno.2017.03.017. PubMed DOI PMC
Haldorsen I.S., Salvesen H.B. What Is the Best Preoperative Imaging for Endometrial Cancer? Curr. Oncol. Rep. 2016;18:25. doi: 10.1007/s11912-016-0506-0. PubMed DOI PMC
Fasmer K.E., Gulati A., Dybvik J.A., Wagner-Larsen K.S., Lura N., Salvesen Ø. Preoperative pelvic MRI and 2-[(18)F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer-time to revisit current imaging guidelines? Eur. Radiol. 2022;33:221–232. doi: 10.1007/s00330-022-08949-3. PubMed DOI PMC
Reijnen C., IntHout J., Massuger L.F., Strobbe F., Küsters-Vandevelde H.V., Haldorsen I.S., Snijders M.P., Pijnenborg J.M. Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis. Oncologist. 2019;24:e880–e890. doi: 10.1634/theoncologist.2019-0117. PubMed DOI PMC
Tuomi T., Pasanen A., Luomaranta A., Leminen A., Bützow R., Loukovaara M. Risk-stratification of endometrial carcinomas revisited: A combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease. Gynecol. Oncol. 2015;137:23–27. doi: 10.1016/j.ygyno.2015.01.545. PubMed DOI
Kang S., Kang W.D., Chung H.H., Jeong D.H., Seo S.-S., Lee J.-M., Lee J.-K., Kim J.-W., Kim S.-M., Park S.-Y., et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: A Korean gynecologic oncology group study. J. Clin. Oncol. 2012;30:1329–1334. doi: 10.1200/JCO.2011.38.2416. PubMed DOI
Kang S., Nam J.-H., Bae D.-S., Kim J.-W., Kim M.-H., Chen X., No J.-H., Lee J.-M., Watari H., Kim S.M., et al. Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer. 2017;123:263–272. doi: 10.1002/cncr.30349. PubMed DOI
Tsikouras P., Koukouli Z., Bothou A., Manav B., Iatrakis G., Zervoudis S. Preoperative assessment in endometrial cancer. Is triage for lymphadenectomy possible? J. Buon. 2017;22:34–43. PubMed
Reijnen C., Gogou E., Visser N.C.M., Engerud H., Ramjith J., Van Der Putten L.J.M., Van De Vijver K., Santacana M., Bronsert P., Bulten J., et al. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Med. 2020;17:e1003111. doi: 10.1371/journal.pmed.1003111. PubMed DOI PMC
Jamieson A., Thompson E.F., Huvila J., Leung S., Lum A., Morin C., Ennour-Idrissi K., Sebastianelli A., Renaud M.-C., Gregoire J., et al. Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. Gynecol. Oncol. 2022;165:376–384. doi: 10.1016/j.ygyno.2022.01.025. PubMed DOI
Anton C., e Silva A.S., Baracat E.C., Dogan N.U., Köhler C., Carvalho J.P., di Favero G.M. A novel model to estimate lymph node metastasis in endometrial cancer patients. Clinics. 2017;72:30–35. doi: 10.6061/clinics/2017(01)06. PubMed DOI PMC
Bogani G., Gostout B.S., Dowdy S.C., Multinu F., Casarin J., Cliby W.A., Frigerio L., Kim B., Weaver A.L., Glaser G.E., et al. Clinical Utility of Preoperative Computed Tomography in Patients With Endometrial Cancer. Int. J. Gynecol. Cancer. 2017;27:1685–1693. doi: 10.1097/IGC.0000000000001076. PubMed DOI
Steenbeek M.P., Bulten J., Snijders M.P., Lombaers M., Hendriks J., Brand M.V.D., Kraayenbrink A.A., Massuger L.F., Sweegers S., de Hullu J.A., et al. Fallopian tube abnormalities in uterine serous carcinoma. Gynecol. Oncol. 2020;158:339–346. doi: 10.1016/j.ygyno.2020.04.707. PubMed DOI
Visser N.C.M., Bulten J., Van Der Wurff A.A.M., Boss E.A., Bronkhorst C.M., Feijen H.W.H., Haartsen J.E., Van Herk H.A.D.M., De Kievit I.M., Klinkhamer P.J.J.M., et al. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: A multicentre prospective cohort study. BMC Cancer. 2015;15:487. doi: 10.1186/s12885-015-1487-3. PubMed DOI PMC
Visser N.C., van der Wurff A.A., IntHout J., Reijnen C., Dabir P.D., Soltani G.G., Alcala L.S., Boll D., Bronkhorst C.M., Bult P., et al. Improving preoperative diagnosis in endometrial cancer using systematic morphological assessment and a small immunohistochemical panel. Hum. Pathol. 2021;117:68–78. doi: 10.1016/j.humpath.2021.08.006. PubMed DOI
Faria S.C., Sagebiel T., Balachandran A., Devine C., Lal C., Bhosale P.R. Imaging in endometrial carcinoma. Indian J. Radiol. Imaging. 2015;25:137–147. doi: 10.4103/0971-3026.155857. PubMed DOI PMC
Lee J.-Y., Jung D.-C., Park S.-H., Lim M.-C., Seo S.-S., Park S.-Y., Kang S. Preoperative prediction model of lymph node metastasis in endometrial cancer. Int. J. Gynecol. Cancer. 2010;20:1350–1355. PubMed
Reijnen C., Visser N.C., Kasius J.C., Boll D., Geomini P.M., Ngo H., van Hamont D., Pijlman B.M., Vos M.C., Bulten J., et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: A multicenter prospective cohort study. J. Gynecol. Oncol. 2019;30:e70. doi: 10.3802/jgo.2019.30.e70. PubMed DOI PMC
Solmaz U., Mat E., Dereli M., Turan V., Güngördük K., Hasdemir P.S., Tosun G., Dogan A., Ozdemir A., Adiyeke M., et al. Lymphovascular space invasion and cervical stromal invasion are independent risk factors for nodal metastasis in endometrioid endometrial cancer. Aust. N. Z. J. Obstet. Gynaecol. 2015;55:81–86. doi: 10.1111/ajo.12321. PubMed DOI
Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021;31:12–39. doi: 10.1136/ijgc-2020-002230. PubMed DOI
Hamilton C.A., Pothuri B., Arend R.C., Backes F.J., Gehrig P.A., Soliman P.T., Thompson J.S., Urban R.R., Burke W.M. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecol. Oncol. 2021;160:817–826. doi: 10.1016/j.ygyno.2020.12.021. PubMed DOI
Sebastianelli A., Renaud M.-C., Grégoire J., Roy M., Plante M. Preoperative CA 125 tumour marker in endometrial cancer: Correlation with advanced stage disease. J. Obstet. Gynaecol. Can. 2010;32:856–860. doi: 10.1016/S1701-2163(16)34657-6. PubMed DOI
Schmidt M., Segev Y., Sadeh R., Suzan E., Feferkorn I., Kaldawy A., Kligun G., Lavie O. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma. Int. J. Gynecol. Cancer. 2018;28:1311–1317. doi: 10.1097/IGC.0000000000001300. PubMed DOI
Cetinkaya N., Selcuk I., Ozdal B., Meydanli M.M., Gungor T. Diagnostic Impacts of Serum CA-125 Levels, Pap Smear Evaluation, and Endometrial Sampling in Women with Endometrial Clear Cell Carcinoma. Oncol. Res. Treat. 2016;39:283–288. doi: 10.1159/000445860. PubMed DOI
Bollineni V.R., Ytre-Hauge S., Bollineni-Balabay O., Salvesen H.B., Haldorsen I.S. High Diagnostic Value of <sup>18</sup>F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. J. Nucl. Med. 2016;57:879–885. PubMed
D’Ambrosio V., Brunelli R., Musacchio L., Del Negro V., Vena F., Boccuzzi G., Boccherini C., Di Donato V., Piccioni M.G., Panici P.B., et al. Adnexal masses in pregnancy: An updated review on diagnosis and treatment. Tumori. 2021;107:12–16. doi: 10.1177/0300891620909144. PubMed DOI
Jacobs I., Bast R.C., Jr. The CA 125 tumour-associated antigen: A review of the literature. Hum. Reprod. 1989;4:1–12. doi: 10.1093/oxfordjournals.humrep.a136832. PubMed DOI
Zaami S., Stark M., Signore F., Gullo G., Marinelli E. Fertility preservation in female cancer sufferers: (only) a moral obligation? Eur. J. Contracept. Reprod. Health Care. 2022;27:335–340. doi: 10.1080/13625187.2022.2045936. PubMed DOI
Zaami S., Stark M., Signore F., Gullo G., Marinelli E. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health. 2008;8:8. PubMed PMC
Haldorsen I.S., Berg A., Werner H.M., Magnussen I.J., Helland H., Salvesen O., Trovik J., Salvesen H.B. Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas. Gynecol. Oncol. 2012;126:413–418. doi: 10.1016/j.ygyno.2012.05.009. PubMed DOI
Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. PubMed DOI PMC
Gulìa C., Signore F., Gaffi M., Gigli S., Votino R., Nucciotti R., Bertacca L., Zaami S., Baffa A., Santini E., et al. Y RNA: An Overview of Their Role as Potential Biomarkers and Molecular Targets in Human Cancers. Cancers. 2020;12:1238. doi: 10.3390/cancers12051238. PubMed DOI PMC
Piergentili R., Zaami S., Cavaliere A., Signore F., Scambia G., Mattei A., Marinelli E., Gulia C., Perelli F. Non-Coding RNAs as Prognostic Markers for Endometrial Cancer. Int. J. Mol. Sci. 2021;22:3151. doi: 10.3390/ijms22063151. PubMed DOI PMC
